Digitalis Ventures

Galatea Bio is a biotechnology company focused on leveraging genetic diversity and advanced data analytics to drive innovations in healthcare. They provide clinical testing, genomic services, and biopharma R&D, while emphasizing the importance of underrepresented populations in genetic research.

Gallant is building a new category of veterinary medicine: ready-to-use regenerative therapies that target disease at its source rather than just treat symptoms.

Alterome is a clinical-stage biotechnology company focused on developing targeted therapies for cancer, utilizing structure-guided drug discovery and precision oncology.

Alcea Therapeutics is a preclinical therapeutics company focused on treating airway inflammation through immune tolerance.

Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new RNA medicines for systemic and renal diseases. With our STRIKE (Selectively Targeting RNA Into KidnEy) platform, we use a proprietary approach that harnesses a natural, endogenous mechanism to target oligonucleotide medicines to the kidney.

Aviceda Therapeutics is a clinical-stage biotech company focused on developing novel therapies for immune-mediated diseases, particularly targeting macular degeneration, a leading cause of blindness.

Matchpoint Therapeutics is a biotechnology company pioneering the discovery of precision covalent medicines to transform the treatment of immune diseases. The company utilizes its Advanced Covalent Exploration (ACE) platform to target disease-causing proteins with innovative covalent chemistry.

Nuvig Therapeutics is pioneering novel therapies for chronic autoimmune diseases, focusing on next-generation immune modulators that treat underlying inflammatory conditions without compromising immune function.

Code Ocean provides a cloud-based platform for computational science, enabling users to run analyses, build pipelines, and reproduce results securely and efficiently. It offers tools for managing code, data, and machine learning models, with a focus on reproducibility and collaboration.

Findhelp connects people to social care resources in their neighborhoods, offering a platform for food, housing, financial assistance, health care, and more.

Positive Development provides family-centered, play-based autism care, focusing on the unique needs of children with autism and their families. Their approach emphasizes emotional and intellectual development through personalized therapy plans.

Invests in early-stage life sciences companies, often backing founders when they are no more than an idea.

Bioscience investor translating grant-funded research into venture-scale companies, with a pipeline centered on engineering biology using robotic cloud labs and computational design for human health and planetary sustainability. The firm grew directly out of a philanthropic grants program at the Thiel Foundation that funded highly speculative science before spinning into a traditional venture fund.

Invests in disruptive, technology-focused startups; established in 1999.

MBX Capital is a venture capital fund with a "deep health" thesis that treats health as a systems problem. They invest across biology, chemistry, AI/ML, robotics, and clinical medicine to back companies addressing root causes of environmental health and healthcare infrastructure challenges. The fund makes $1–2.5M first checks targeting ≥5% equity and operates with a private "Atom Network" of hundreds of scientific and clinical experts who help source and vet investments.

F-Prime Capital is one of the few large global VC firms that has built over 30 companies from scratch rather than just backing existing startups, drawing on Fidelity's resources to combine deep healthcare and technology expertise with a structured company-formation engine that pulls together academic founders across multiple geographies. The firm operates with sister fund Eight Roads to create one of the broadest cross-border VC footprints, systematically syndicating ideas across the U.S., Europe, China, Japan, India, and Israel while maintaining a distinctive "technical-risk-yes, regulatory-risk-no" filter that avoids heavy regulatory categories like broad antibiotics in favor of rare diseases and gene therapy where FDA pathways are clearer.